<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pipeline - 4E Therapeutics Inc</title>
    <link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/font-awesome/4.4.0/css/font-awesome.min.css">
    <link href="https://fonts.googleapis.com/css2?family=Didact+Gothic&family=Raleway:wght@100;200;300;400;500;600;700;800;900&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="css/animate.min.css" />
    <link rel="stylesheet" href="css/fullpage.css">
    <link rel="stylesheet" href="css/style.css">
</head>

<body>


    <div id="fullpage">

        <div class="section" id="section1">
            <div class="fp-bg"></div>
            <div class="section-content">
                <video class="video-bg" preload="auto" loop="" autoplay="" muted="" playsinline="">
                    <source src="https://4etherapeutics.com/wp-content/uploads/2021/10/neuron-bg-video.mp4"
                        type="video/mp4">
                </video>

                <div class="content-pos">
                    <div class="arrow">
                        <p><span></span> PIPELINE </p>
                    </div>

                    <h3 class="animate__animated"> 4E Therapeutics is developing a pipeline of <br> non-opioid therapeutic assets to target pain.</h3>
                </div>

                <div class="bottom-arrow" style="display: none;">
                    <i class="fa fa-long-arrow-down" aria-hidden="true"></i>
                </div>
            </div>
        </div>

        <div class="section" id="section2">
            <div class="fp-bg"></div>

            <div class="content-pos content-sec">
                <h3 class="animate__animated">We currently have 3 areas of focus:</h3>

                <div class="box-heading">
                    <ul>
                        <li>Phase</li>
                        <li>Discovery</li>
                        <li>IND-Enabling</li>
                        <li>Phase 1</li>
                        <li>Phase 2</li>
                        <li>Phase 3</li>
                    </ul>

                    <div class="line"></div>

                    <div class="row">
                        <div class="col4">
                            <h3>Neuropathic Pain</h3>
                            <h4>4ET1103</h4>
                        </div>

                        <div class="col8">
                            <p>IND-Enabling</p>
                            <div class="progress">
                                <div class="progress-done progress-done2 bg-1" data-done="30"></div>
                            </div>
                            <div class="arrow-sec">
                                <a href="javascript:;"><span></span>LEARN MORE</a>
                            </div>
                        </div>
                    </div>

                    <div class="row">
                        <div class="col4">
                            <h3>Migraine Pain</h3>
                            <h4>MNK-elF4E</h4>
                        </div>

                        <div class="col8">
                            <p>Discovery</p>
                            <div class="progress">
                                <div class="progress-done progress-done2 bg-1 data-width1" data-done="20"></div>
                            </div>
                            <div class="arrow-sec">
                                <a href="javascript:;"><span></span>LEARN MORE</a>
                            </div>
                        </div>
                    </div>

                    <div class="row">
                        <div class="col4">
                            <h3>Acute Pain </h3>
                            <h4>GPCR ENRICHED IN HUMAN DRG NEURONS</h4>
                        </div>

                        <div class="col8">
                            <p>Discovery</p>
                            <div class="progress">
                                <div class="progress-done progress-done2 bg-1 data-width2" data-done="60"></div>
                            </div>
                            <div class="arrow-sec">
                                <a href="javascript:;"><span></span>LEARN MORE</a>
                            </div>
                        </div>
                    </div>

                    <div class="line"></div>
                </div>
            </div>
        </div>

        <div class="section" id="section3">
            <div class="fp-bg"></div>
            <div class="content-pos content-sec">
                <div class="row">
                    <div class="col4">
                        <svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="50" height="50" viewBox="0 0 32 32" class="animate__animated">
                            <path d="M25.357 24.265c-0.24 0-0.472-0.131-0.589-0.357l-8.025-15.156c-0.172-0.324-0.047-0.731 0.279-0.904 0.325-0.171 0.727-0.044 0.901 0.277l8.024 15.157c0.172 0.325 0.048 0.729-0.277 0.903-0.103 0.056-0.208 0.080-0.312 0.080zM6.423 24.265c-0.095 0-0.192-0.024-0.283-0.065-0.333-0.155-0.476-0.552-0.32-0.885l7.135-15.157c0.157-0.332 0.555-0.475 0.888-0.319s0.476 0.553 0.32 0.887l-7.135 15.157c-0.115 0.241-0.355 0.383-0.605 0.383zM23.271 28h-14.383c-0.368 0-0.667-0.3-0.667-0.667s0.299-0.667 0.667-0.667h14.383c0.367 0 0.667 0.3 0.667 0.667s-0.299 0.667-0.667 0.667zM4.667 24c1.841 0 3.333 1.492 3.333 3.333s-1.492 3.333-3.333 3.333-3.333-1.492-3.333-3.333 1.492-3.333 3.333-3.333zM4.667 22.667c-2.573 0-4.667 2.093-4.667 4.667s2.093 4.667 4.667 4.667 4.667-2.093 4.667-4.667-2.093-4.667-4.667-4.667v0zM27.333 24c1.841 0 3.333 1.492 3.333 3.333s-1.492 3.333-3.333 3.333-3.333-1.492-3.333-3.333 1.492-3.333 3.333-3.333zM27.333 22.667c-2.573 0-4.667 2.093-4.667 4.667s2.093 4.667 4.667 4.667 4.667-2.093 4.667-4.667-2.093-4.667-4.667-4.667v0zM15.333 1.333c1.841 0 3.333 1.492 3.333 3.333s-1.492 3.333-3.333 3.333-3.333-1.492-3.333-3.333 1.492-3.333 3.333-3.333zM15.333 0c-2.573 0-4.667 2.093-4.667 4.667s2.093 4.667 4.667 4.667c2.573 0 4.667-2.093 4.667-4.667s-2.093-4.667-4.667-4.667v0z"></path>
                            </svg>
                        <h4 class="animate__animated">Neuropathic Pain</h4>
                    </div>
                    <div class="col8">
                        <div class="right-text">
                            <p>4E Therapeutics has completed our medicinal chemistry optimization program in which <span>over 150 proprietary, small molecule MNK inhibitors</span> were synthesized and evaluated, leading to the discovery of a cohort of peripherally-restricted,
                                orally-bioavailable compounds.</p>
                        </div>
                    </div>
                </div>

                <div class="box-heading">
                    <ul>
                        <li>Phase</li>
                        <li>Discovery</li>
                        <li>IND-Enabling</li>
                        <li>Phase 1</li>
                        <li>Phase 2</li>
                        <li>Phase 3</li>
                    </ul>

                    <div class="line"></div>

                    <div class="row">
                        <div class="col4">
                            <h3>4ET1103</h3>
                            <h4>SELECTED AS LEAD <br> COMPOUND</h4>
                        </div>

                        <div class="col8">
                            <p>IND-Enabling</p>
                            <div class="progress">
                                <div class="progress-done progress-done3 bg-3" data-done="50"></div>
                            </div>

                            <div class="para-p">
                                <p>Having met our stringent preclinical safety and efficacy criteria, 4ET1103 is highly efficacious in multiple animal models of pain and is well-tolerated in rodents and dogs. Significantly, 4ET1103 blocks evoked MNK activity
                                    in human dorsal root ganglion neurons from organ donors, underscoring its translational potential.</p>
                                <h4>4ET1103 HAS ENTERED IND-ENABLING STUDIES AND IS EXPECTED TO BE READY FOR CLINICAL TRIALS IN 2024.</h4>
                            </div>
                        </div>
                    </div>

                    <div class="line"></div>
                </div>
            </div>
        </div>

        <div class="section" id="section4">
            <div class="fp-bg"></div>
            <div class="content-pos content-sec">
                <div class="row">
                    <div class="col4">
                        <svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="50" height="50" viewBox="0 0 32 32" class="animate__animated">
                            <path d="M25.357 24.265c-0.24 0-0.472-0.131-0.589-0.357l-8.025-15.156c-0.172-0.324-0.047-0.731 0.279-0.904 0.325-0.171 0.727-0.044 0.901 0.277l8.024 15.157c0.172 0.325 0.048 0.729-0.277 0.903-0.103 0.056-0.208 0.080-0.312 0.080zM6.423 24.265c-0.095 0-0.192-0.024-0.283-0.065-0.333-0.155-0.476-0.552-0.32-0.885l7.135-15.157c0.157-0.332 0.555-0.475 0.888-0.319s0.476 0.553 0.32 0.887l-7.135 15.157c-0.115 0.241-0.355 0.383-0.605 0.383zM23.271 28h-14.383c-0.368 0-0.667-0.3-0.667-0.667s0.299-0.667 0.667-0.667h14.383c0.367 0 0.667 0.3 0.667 0.667s-0.299 0.667-0.667 0.667zM4.667 24c1.841 0 3.333 1.492 3.333 3.333s-1.492 3.333-3.333 3.333-3.333-1.492-3.333-3.333 1.492-3.333 3.333-3.333zM4.667 22.667c-2.573 0-4.667 2.093-4.667 4.667s2.093 4.667 4.667 4.667 4.667-2.093 4.667-4.667-2.093-4.667-4.667-4.667v0zM27.333 24c1.841 0 3.333 1.492 3.333 3.333s-1.492 3.333-3.333 3.333-3.333-1.492-3.333-3.333 1.492-3.333 3.333-3.333zM27.333 22.667c-2.573 0-4.667 2.093-4.667 4.667s2.093 4.667 4.667 4.667 4.667-2.093 4.667-4.667-2.093-4.667-4.667-4.667v0zM15.333 1.333c1.841 0 3.333 1.492 3.333 3.333s-1.492 3.333-3.333 3.333-3.333-1.492-3.333-3.333 1.492-3.333 3.333-3.333zM15.333 0c-2.573 0-4.667 2.093-4.667 4.667s2.093 4.667 4.667 4.667c2.573 0 4.667-2.093 4.667-4.667s-2.093-4.667-4.667-4.667v0z"></path>
                            </svg>
                        <h4 class="animate__animated">Migraine Pain</h4>
                    </div>
                    <div class="col8">
                        <div class="right-text">
                            <p>4E Therapeutics research shows that the MNK-eIF4E signaling pathway is implicated in migraine, and that disrupting this pathway is a promising strategy for inhibiting migraine pain.</p>
                        </div>
                    </div>
                </div>

                <div class="box-heading">
                    <ul>
                        <li>Phase</li>
                        <li>Discovery</li>
                        <li>IND-Enabling</li>
                        <li>Phase 1</li>
                        <li>Phase 2</li>
                        <li>Phase 3</li>
                    </ul>

                    <div class="line"></div>

                    <div class="row">
                        <div class="col4">
                            <h3>MNK-elF4E</h3>
                            <h4>SIGNALING PATHWAY</h4>
                        </div>

                        <div class="col8">
                            <p>Discovery</p>
                            <div class="progress">
                                <div class="progress-done progress-done4 bg-4" data-done="80"></div>
                            </div>

                            <div class="para-p">
                                <p>Building upon these discoveries, 4E is developing small molecule MNK inhibitors into next-generation drugs for the treatment of migraine. We are currently evaluating our MNK inhibitors in animal models of migraine.</p>
                                <h4>A DEVELOPMENT CANDIDATE WILL BE SELECTED IN 2022.</h4>
                            </div>
                        </div>
                    </div>

                    <div class="line"></div>
                </div>
            </div>
        </div>

        <div class="section" id="section5">
            <div class="fp-bg"></div>
            <div class="content-pos content-sec">
                <div class="row">
                    <div class="col4">
                        <svg version="1.1" xmlns="http://www.w3.org/2000/svg" width="50" height="50" viewBox="0 0 32 32" class="animate__animated">
                            <path d="M25.357 24.265c-0.24 0-0.472-0.131-0.589-0.357l-8.025-15.156c-0.172-0.324-0.047-0.731 0.279-0.904 0.325-0.171 0.727-0.044 0.901 0.277l8.024 15.157c0.172 0.325 0.048 0.729-0.277 0.903-0.103 0.056-0.208 0.080-0.312 0.080zM6.423 24.265c-0.095 0-0.192-0.024-0.283-0.065-0.333-0.155-0.476-0.552-0.32-0.885l7.135-15.157c0.157-0.332 0.555-0.475 0.888-0.319s0.476 0.553 0.32 0.887l-7.135 15.157c-0.115 0.241-0.355 0.383-0.605 0.383zM23.271 28h-14.383c-0.368 0-0.667-0.3-0.667-0.667s0.299-0.667 0.667-0.667h14.383c0.367 0 0.667 0.3 0.667 0.667s-0.299 0.667-0.667 0.667zM4.667 24c1.841 0 3.333 1.492 3.333 3.333s-1.492 3.333-3.333 3.333-3.333-1.492-3.333-3.333 1.492-3.333 3.333-3.333zM4.667 22.667c-2.573 0-4.667 2.093-4.667 4.667s2.093 4.667 4.667 4.667 4.667-2.093 4.667-4.667-2.093-4.667-4.667-4.667v0zM27.333 24c1.841 0 3.333 1.492 3.333 3.333s-1.492 3.333-3.333 3.333-3.333-1.492-3.333-3.333 1.492-3.333 3.333-3.333zM27.333 22.667c-2.573 0-4.667 2.093-4.667 4.667s2.093 4.667 4.667 4.667 4.667-2.093 4.667-4.667-2.093-4.667-4.667-4.667v0zM15.333 1.333c1.841 0 3.333 1.492 3.333 3.333s-1.492 3.333-3.333 3.333-3.333-1.492-3.333-3.333 1.492-3.333 3.333-3.333zM15.333 0c-2.573 0-4.667 2.093-4.667 4.667s2.093 4.667 4.667 4.667c2.573 0 4.667-2.093 4.667-4.667s-2.093-4.667-4.667-4.667v0z"></path>
                            </svg>
                        <h4 class="animate__animated">Acute Pain</h4>
                    </div>
                    <div class="col8">
                        <div class="right-text">
                            <p>Peripherally restricted GPCR agonist</p>
                        </div>
                    </div>
                </div>

                <div class="box-heading">
                    <ul>
                        <li>Phase</li>
                        <li>Discovery</li>
                        <li>IND-Enabling</li>
                        <li>Phase 1</li>
                        <li>Phase 2</li>
                        <li>Phase 3</li>
                    </ul>

                    <div class="line"></div>

                    <div class="row">
                        <div class="col4">
                            <h3>GPCR enriched in human DRG neurons</h3>
                        </div>

                        <div class="col8">
                            <p>Discovery</p>
                            <div class="progress">
                                <div class="progress-done progress-done5 bg-5" data-done="40"></div>
                            </div>

                            <div class="para-p">
                                <p>Our approach employs non-brain penetrant small molecules to selectively engage a receptor that is highly expressed in human nociceptors. Peripherally-restricted therapeutics are advantageous because they are devoid of central-nervous-system
                                    side effects, such as impaired cognitive function and physical dependence.</p>
                                <h4>A LEAD COMPOUND WILL BE SELECTED IN 2023.</h4>
                            </div>
                        </div>
                    </div>

                    <div class="line"></div>
                </div>
            </div>
        </div>

        <div class="section" id="section6">
            <div class="fp-bg"></div>

            <div class="publications">
                <h1>Publications</h1>
                <div class="row">
                    <div class="col">
                        <div class="box-se">
                            <p>The Journal of Neuroscience</p>
                            <h4>AUGUST 2, 2017</h4>
                            <h3>The MNK–eIF4E Signaling Axis Contributes to Injury-Induced Nociceptive Plasticity and the Development of Chronic Pain</h3>
                            <a href="#" class="btn-download"><span>DOWNLOAD NOW</span> <i class="fa fa-arrow-right"></i></a>
                        </div>
                    </div>

                    <div class="col">
                        <div class="box-se">
                            <p>Trends in Neurosciences</p>
                            <h4>FEBRUARY 01, 2018</h4>
                            <h2>Translational Control Mechanisms in Persistent Pain</h2>
                            <a href="#" class="btn-download"><span>DOWNLOAD NOW</span> <i class="fa fa-arrow-right"></i></a>
                        </div>
                    </div>

                    <div class="col">
                        <div class="box-se">
                            <p>The Journal of Neuroscience</p>
                            <h4>JANUARY 16, 2019</h4>
                            <h3>Nociceptor Translational Profiling Reveals the Ragulator-Rag GTPase Complex as a Critical Generator of Neuropathic Pain</h3>
                            <a href="#" class="btn-download"><span>DOWNLOAD NOW</span> <i class="fa fa-arrow-right"></i></a>
                        </div>
                    </div>

                    <div class="col">
                        <div class="box-se">
                            <p>Biological Sciences</p>
                            <h4>SEPTEMBER 23, 2019</h4>
                            <h3>MNK-eIF4E signalling is a highly conserved mechanism for sensory neuron axonal plasticity: evidence from <span>Aplysia californica</span></h3>
                            <a href="#" class="btn-download"><span>DOWNLOAD NOW</span> <i class="fa fa-arrow-right"></i></a>
                        </div>
                    </div>

                    <div class="col">
                        <div class="box-se">
                            <p>Neuropsychopharmacology</p>
                            <h4>OCTOBER 07, 2019</h4>
                            <h3>Reversal of peripheral nerve injury-induced neuropathic pain and cognitive dysfunction via genetic and tomivosertib targeting of MNK</h3>
                            <a href="#" class="btn-download"><span>DOWNLOAD NOW</span> <i class="fa fa-arrow-right"></i></a>
                        </div>
                    </div>

                    <div class="col">
                        <div class="box-se">
                            <p>Pharmacological Reviews</p>
                            <h4>JANUARY, 2021</h4>
                            <h3>Pharmacological Manipulation of Translation as a Therapeutic Target for Chronic Pain</h3>
                            <a href="#" class="btn-download"><span>DOWNLOAD NOW</span> <i class="fa fa-arrow-right"></i></a>
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div class="section fp-auto-height" id="section7">
            <div id="footer">
                <div class="row justify-content-center">
                    <div class="box-img">
                        <img loading="lazy" width="512" height="512" src="https://4etherapeutics.com/wp-content/uploads/2021/10/favicon.png" alt="">
                    </div>

                    <div class="box-content">
                        <p>3800 N. Lamar Blvd. <br> Suite 200 <br> Austin, Texas 78756</p>
                        <p>E: <span>info@4etherapuetics.com</span></p>
                        <p><span>Financial Conflict of Interest Policy »</span></p>
                        <p><strong>4E Therapeutics is dedicated to developing innovative and novel <br> treatments for neuropathic pain. </strong></p>
                    </div>
                </div>
            </div>
        </div>

    </div>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/2.1.3/jquery.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fullPage.js/2.7.4/jquery.fullPage.min.js"></script>
    <script src="js/parallax.min.js"></script>
    <script src="js/custom.js"></script>
</body>

</html>